-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus
-
2024-516634-35-00
6
2024-02-01
Convulsive or nonconvulsive benzodiazepine-resistant (established) sta
-
2022-501941-63-00
7
2023-12-13
Multiple myeloma
-
2022-500453-16-00
4
2023-10-30
Multiple Myeloma
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2024-515924-35-00
6
2023-01-16
New-Onset Post-Operative Atrial Fibrillation after CABG
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2023-507461-26-00
5
2022-09-22
Newly diagnosed acute myeloid leukemia (AML)
-
2023-509278-41-00
5
2022-07-04
Early Stage Follicular LymphOma
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-514556-32-00
5
2017-02-15
Adult critically ill patients with severe vitamin D deficiency
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516745-39-00
4
2025-07-11
Cutaneous lupus erythematosus
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-511881-35-00
5
2024-12-17
Prurigo Nodularis